Search

Your search keyword '"Koc Y"' showing total 362 results
Start Over Author "Koc Y"
362 results on '"Koc Y"'

1. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT

Author

Potter, V., Gras, L., Koster, L., Kroger, N., Sockel, K., Ganser, A., Finke, J., Labussiere-Wallet, H., Peffault de Latour, R., Koc, Y., Salmenniemi, U., Smidstrup Friis, L., Jindra, P., Schroeder, T., Tischer, J., Arat, M., Pascual Cascon, M., de Wreede, L. C., Hayden, P., Raj, K., Drozd-Sokolowska, J., Scheid, C., McLornan, D. P., Robin, M., and Yakoub-Agha, I.

Published
2024
Full Text
View/download PDF

2. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Author

Salas, M. Q., Eikema, D. -J., Koster, L., Maertens, J., Passweg, J., Finke, J., Broers, A. E. C., Koc, Y., Kroger, N., Ozkurt, Z. N., Pascual-Cascon, M. J., Platzbecker, U., Van Gorkom, G., Schroeder, T., Lopez-Lorenzo, J. L., Martino, Michelangelo, Chiusolo, Patrizia, Kaufmann, M., Onida, F., Gurnari, C., Scheid, C., Drozd-Sokolowska, J., Raj, K., Robin, M., Mclornan, D. P., Martino M., Chiusolo P. (ORCID:0000-0002-1355-1587), Salas, M. Q., Eikema, D. -J., Koster, L., Maertens, J., Passweg, J., Finke, J., Broers, A. E. C., Koc, Y., Kroger, N., Ozkurt, Z. N., Pascual-Cascon, M. J., Platzbecker, U., Van Gorkom, G., Schroeder, T., Lopez-Lorenzo, J. L., Martino, Michelangelo, Chiusolo, Patrizia, Kaufmann, M., Onida, F., Gurnari, C., Scheid, C., Drozd-Sokolowska, J., Raj, K., Robin, M., Mclornan, D. P., Martino M., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

We retrospectively compared outcomes of 404 MDS patients undergoing 1st matched sibling donor allo-HCT receiving either PTCy-based (n = 66) or other “conventional prophylaxis” (n = 338; mostly calcineurin inhibitor + methotrexate or MMF). Baseline characteristics were balanced, except for higher use of myeloablative regimens in the PTCy group (52.3% vs. 38.2%, p = 0.047). Incidences of neutrophil (Day +28: 89% vs. 97%, p = 0.011) and platelet (Day +100: 89% vs. 97%, p < 0.001) engraftment were lower for PTCy-based. Day +100 cumulative incidences of grade II–IV and III–IV aGVHD, and 5-year CI of extensive cGVHD were 32%, 18% and 18% for PTCy-based and 25% (p = 0.3), 13% (p = 0.4) and 31% (p = 0.09) for the conventional cohort. Five-year OS (51% vs. 52%, p = 0.6) and GRFS (33% vs. 25%, p = 0.6) were similar between groups. Patients receiving PTCy had a trend to a lower cumulative incidence of relapse (20% vs. 33%, p = 0.06), not confirmed on multivariable analysis (p = 0.3). Although higher NRM rates were observed in patients receiving PTCy (32% vs. 21%, p = 0.02) on univariate analysis, this was not confirmed on multivariate analysis (HR 1.46, p = 0.18), and there was no resultant effect on OS (HR 1.20, p = 0.5). Based on these data, PTCy prophylaxis appears to be an attractive option for patients with MDS undergoing MSD allo-HCT.

Published
2024

3. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT

Author

Potter, V., primary, Gras, L., additional, Koster, L., additional, Kroger, N., additional, Sockel, K., additional, Ganser, A., additional, Finke, J., additional, Labussiere-Wallet, H., additional, Peffault de Latour, R., additional, Koc, Y., additional, Salmenniemi, U., additional, Smidstrup Friis, L., additional, Jindra, P., additional, Schroeder, T., additional, Tischer, J., additional, Arat, M., additional, Pascual Cascon, M., additional, de Wreede, L. C., additional, Hayden, P., additional, Raj, K., additional, Drozd-Sokolowska, J., additional, Scheid, C., additional, McLornan, D. P., additional, Robin, M., additional, and Yakoub-Agha, I., additional

Published
2023
Full Text
View/download PDF

4. EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)

Author

Wiktor-Jedrzejczak, W., Drozd-Sokolowska, J., Eikema, D. J., Hoek, J., Potter, M., Wulf, G., Sellner, L., Ljungman, P., Chevallier, P., Volin, L., Koc, Y., Martin, S., Bunjes, D., Rovira, M., Itälä-Remes, M., Foá, R., Deconinck, E., Gedde-Dahl, T., Cornelissen, J., Collin, M., Brecht, A., Patel, A., de Groot, M., Reményi, P., Nagler, A., Finke, J., Turlure, P., Iacobelli, S., van Biezen, A., Schetelig, J., Kröger, N., and Dreger, P.

Published
2019
Full Text
View/download PDF

5. P1371: GRAFT-VERSUS-HOST DISEASE OFFERS NO GRAFT-VERSUS-LEUKEMIA ADVANTAGE IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AFTER HAPLO-IDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE

Author

Shimoni, A., primary, Peczynski, C., additional, Labopin, M., additional, Angelucci, E., additional, Koc, Y., additional, Arat, M., additional, Tischer, J., additional, Sica, S., additional, Gülbas, Z., additional, Socié, G., additional, Blaise, D., additional, Pioltelli, P., additional, Ozdogu, H., additional, Vydra, J., additional, Ciceri, F., additional, Nagler, A., additional, and Mohty, M., additional

Published
2022
Full Text
View/download PDF

6. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT

Author

Forcade, E., Chevret, S., Finke, J., Ehninger, G., Ayuk, F., Beelen, D., Koster, L, Ganser, A., Volin, L., Sengeloev, H., Michallet, M., Tischer, J., Jindra, P., Cascon, M.J.P., Koc, Y., Arat, M., Tomaszewska, A., Hayden, P., Witte, T.J. de, Yakoub-Agha, I., Kröger, N., Forcade, E., Chevret, S., Finke, J., Ehninger, G., Ayuk, F., Beelen, D., Koster, L, Ganser, A., Volin, L., Sengeloev, H., Michallet, M., Tischer, J., Jindra, P., Cascon, M.J.P., Koc, Y., Arat, M., Tomaszewska, A., Hayden, P., Witte, T.J. de, Yakoub-Agha, I., and Kröger, N.

Abstract

Item does not contain fulltext, While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.

Published
2022

7. Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation

Author

Ruggeri, L., Eikema, D. -J., Bondanza, A., Noviello, M., van Biezen, A., de Wreede, L. C., Crucitti, L., Vago, L., Ciardelli, S., Bader, P., Koc, Y., Locatelli, Franco, Veelken, J. H., Gruhn, B., Evans, P., Chabannon, C., Toubert, A., Velardi, A., Locatelli F. (ORCID:0000-0002-7976-3654), Ruggeri, L., Eikema, D. -J., Bondanza, A., Noviello, M., van Biezen, A., de Wreede, L. C., Crucitti, L., Vago, L., Ciardelli, S., Bader, P., Koc, Y., Locatelli, Franco, Veelken, J. H., Gruhn, B., Evans, P., Chabannon, C., Toubert, A., Velardi, A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

Transplacental trafficking of maternal and fetal cells during pregnancy establishes long-term reciprocal microchimerism in both mother and child. Consequently, the maternal immune system may become sensitized to paternal histocompatibility antigens. It has been hypothesized that mother's “exposure” to paternal HLA haplotype antigens during pregnancy may affect the outcome of hematopoietic stem cell transplantation (HSCT) when the mother serves as a donor for the child. In T cell-depleted HLA haploidentical HSCT, maternal donors have been associated with improved transplantation outcomes. The present retrospective multicenter study, conducted on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society of Blood and Marrow Transplantation, involved 409 patients (102 pediatric and 307 adult) with acute leukemia who underwent HLA-haploidentical HSCT. The goal of the study was to evaluate the role of maternal donors in a large cohort of haploidentical transplantation recipients. Transplantation from maternal donors was associated with a lower relapse incidence in T cell-depleted HSCTs (hazard ratio [HR], 2.13; 95% confidence interval [CI], 1.16 to 3.92; P = .018) as well as in a limited series of unmanipulated in vivo T cell-depleted HSCTs (HR, 4.15; 95% CI, 0.94 to 18.35; P = .06), along with better graft-versus-host disease/relapse-free survival (GRFS) in T cell-depleted HSCT (HR, 1.67; 95% CI, 1.02 to 2.73; P = .04). These results indicate that the mother is the preferred donor to provide better GRFS in T cell-depleted HLA-haploidentical HSCT for acute leukemia.

Published
2022

11. Quando amare fa male: la pervasività dello stigma verso la non-monogamia consensuale

Author

Ciaffoni S., Koc Y., Moscatelli S., and Ciaffoni, S., Koc, Y., Moscatelli S.

Subjects
Non monogamia consensuale, Stigma, Norme sociali descrittive, Norme sociali ingiuntive
Abstract

Avere una relazione romantica soddisfacente ha delle conseguenze positive sulla salute e sul benessere, rispondendo ai bisogni di supporto emotivo, di cura e di gratificazione sessuale (Balzarini et al., 2019). Tuttavia, per alcuni condurre una vita romantica secondo i propri bisogni e valori può rivelarsi problematico, a causa della mancata accettazione sociale di preferenze relazionali non tradizionali da parte delle altre persone. È questo il caso di tutte quelle persone in relazioni consensualmente non-monogame (CNM; Conley et al., 2012). L’obiettivo di questo articolo è quello di esaminare il fenomeno, sulla base dei pochi studi di stampo psicosociale sinora condotti. In particolare, soffermandoci sullo stigma che colpisce le persone CNM, proponiamo un’analisi della sua possibile origine e delle strategie per ridurlo.

Published
2021

12. Beneficial role of CD8+T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias

Author

Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D.J., Bonini, C., Chabannon, C., Werf, S. van der, Biezen, A. van, Wreede, L.C. de, Crucitti, L., Vago, L., Merluzzi, M., Massei, M.S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, F., Ciceri, F., Toubert, A., Velardi, A., Bernardo, M.E., Dazzi, F., Ellard, R., Fleischhauer, K., Greco, R., Hudecek, M., Kohl, U., Kuball, J., Malard, F., Pedrazzoli, P., Rocha, V., Ruggeri, A., Urbano-Ispizua, A., Wang, J.F., Wieten, L., EBMT Cell Therapy Immunobiol Worki, Bondanza, Attilio, Ruggeri, Loredana, Noviello, Maddalena, Eikema, Dirk-Jan, Bonini, Chiara, Chabannon, Christian, van der Werf, Steffie, van Biezen, Anja, de Wreede, Liesbeth C., Crucitti, Lara, Vago, Luca, Merluzzi, Mara, Massei, Maria Speranza, Veelken, Hendrik, Koc, Yener, Bader, Peter, Gruhn, Bernd, Locatelli, Franco, Ciceri, Fabio, Toubert, Antoine, Velardi, Andrea, MUMC+: DA TI Laboratorium (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: DA TI Staf (9)

Subjects
Male, Oncology, BLOOD, COUNT, Medizin, CHILDREN, CD8-Positive T-Lymphocytes, DISEASE, 0302 clinical medicine, Risk Factors, hemic and lymphatic diseases, Cytotoxic T cell, Registries, Child, INDEX, Leukemia, Hematology, Middle Aged, RECOVERY, Haematopoiesis, surgical procedures, operative, medicine.anatomical_structure, Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, Transplantation, Child, Preschool, 030220 oncology & carcinogenesis, HSCT, Female, Stem cell, Adult, medicine.medical_specialty, Adolescent, T cell, Human leukocyte antigen, Young Adult, 03 medical and health sciences, CD8-positive T-lymphocytes, haematopoietic stem cell transplantation, risk factors, Internal medicine, SCORE, medicine, Humans, IMMUNOTHERAPY, Aged, business.industry, ADULTS, BONE-MARROW-TRANSPLANTATION, Transplantation, Haploidentical, business, CD8, Stem Cell Transplantation, 030215 immunology, RESPONSES
Abstract

HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001-2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.

Published
2019
Full Text
View/download PDF

13. Intergenerational conflicts of interest and prosocial behavior during the COVID-19 pandemic

Author

Jin, S., Balliet, D., Romano, A., Spadaro, G., van Lissa, C.J., Agostini, M., Bélanger, J.J., Gützkow, B., Kreienkamp, J., Leander, N.P., Abakoumkin, G., Khaiyom, J.H.A., Ahmedi, V., Akkas, H., Almenara, C.A., Kurapov, A., Atta, M., Bagci, S.C., Basel, S., Kida, E.B., Buttrick, N.R., Chobthamkit, P., Choi, H.-S., Cristea, M., Csaba, S., Damnjanović, Kaja, Danyliuk, I., Dash, A., Di Santo, D., Douglas, K.M., Enea, V., Faller, D.G., Fitzsimons, G., Gheorghiu, A., Gómez, Á., Han, Q., Helmy, M., Hudiyana, J., Jeronimus, B.F., Jiang, D.-Y., Jovanović, V., Kamenov, Ž., Kende, Anna, Keng, S.-L., Kieu, T.T.T., Koc, Y., Kovyazina, K., Kozytska, I., Krause, J., Kruglanski, A.W., Kutlaca, M., Lantos, Nora Anna, Lemay, E.P., Lesmana, C.B.J., Louis, W.R., Lueders, A., Malik, N.I., Martinez, A., McCabe, K.O., Mehulić, J., Milla, M.N., Mohammed, I., Molinario, E., Moyano, M., Muhammad, H., Mula, S., Muluk, H., Myroniuk, S., Najafi, R., Nisa, C.F., Nyúl, B., O'Keefe, P.A., Osuna, J.J.O., Osin, E.N., Park, J., Pica, G., Pierro, A., Rees, J., Reitsema, A.M., Resta, E., Rullo, M., Ryan, M.K., Samekin, A., Santtila, P., Sasin, E., Schumpe, B.M., Selim, Heyla A., Stanton, M.V., Stroebe, W., Sultana, S., Sutton, R.M., Tseliou, E., Utsugi, A., van Breen, J.A., van Veen, K., vanDellen, M.R., Vázquez, A., Wollast, R., Yeung, V.W.-L., Zand, S., Žeželj, Iris, Zheng, B., Zick, A., Zúñiga, C., PsyCorona Collaboration, Social Psychology, IBBA, Developmental Psychology, Organizational Psychology, Research programme OB, and Research programme GEM

Subjects
Age, COVID-19, Social dilemma, Prosocial behavior, Cross-cultural, Coronavirus disease 2019 (COVID-19), 050109 social psychology, Disease, Economic hardship, 050105 experimental psychology, Developmental psychology, age, social dilemma, prosocial behavior, cross-cultural, SDG 3 - Good Health and Well-being, Pandemic, 0501 psychology and cognitive sciences, Psychology(all), General Psychology, Social distance, Age, COVID-19, Cross-cultural, Prosocial behavior, Social dilemma, 05 social sciences, 3. Good health, Psychology
Abstract

El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado. The COVID-19 pandemic presents threats, such as severe disease and economic hardship, to people of different ages. These threats can also be experienced asymmetrically across age groups, which could lead to generational differences in behavioral responses to reduce the spread of the disease. We report a survey conducted across 56 societies (N = 58,641), and tested pre-registered hypotheses about how age relates to (a) perceived personal costs during the pandemic, (b) prosocial COVID-19 responses (e.g., social distancing), and (c) support for behavioral regulations (e.g., mandatory quarantine, vaccination). We further tested whether the relation between age and prosocial COVID-19 responses can be explained by perceived personal costs during the pandemic. Overall, we found that older people perceived more costs of contracting the virus, but less costs in daily life due to the pandemic. However, age displayed no clear, robust associations with prosocial COVID-19 responses and support for behavioral regulations. We discuss the implications of this work for understanding the potential intergenerational conflicts of interest that could occur during the COVID-19 pandemic. New York University Abu Dhabi

Published
2021
Full Text
View/download PDF

14. Is an Emphasis on Dignity, Honor and Face more an Attribute of Individuals or of Cultural Groups?

Author

Smith, P.B. Easterbrook, M.J. Koc, Y. Lun, V.M.-C. Papastylianou, D. Grigoryan, L. Torres, C. Efremova, M. Hassan, B. Abbas, A. Ahmad, A.H. al-Bayati, A. Selim, H.A. Anderson, J. Cross, S.E. Delfino, G.I. Gamsakhurdia, V. Gavreliuc, A. Gavreliuc, D. Gul, P. Günsoy, C. Hakobjanyan, A. Lay, S. Lopukhova, O. Hu, P. Sunar, D. Texeira, M.L.M. Tripodi, D. Diaz Rivera, P.E. van Osch, Y. Yuki, M. Ogusu, N. Kwantes, C.T. Diaz-Loving, R. Pérez-Floriano, L. Chaleeraktrakoon, T. Chobthamkit, P.

Abstract

This study compares the individual-level and sample-level predictive utility of a measure of the cultural logics of dignity, honor, and face. University students in 29 samples from 24 nations used a simple measure to rate their perceptions of the interpersonal cultural logic characterizing their local culture. The nomological net of these measures was then explored. Key dependent measures included three different facets of independent versus interdependent self-construal, relevant attitudes and values, reported handling of actual interpersonal conflicts, and responses to normative settings. Multilevel analyses revealed both individual- and sample-level effects but the dignity measure showed more individual-level effects, whereas sample-level effects were relatively more important with the face measure. The implications of this contrast are discussed. © 2020 SAGE Publications.

Published
2021

15. Total body irradiation plus fludarabine compared to busulfan plus fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, JL, Fegueux, N, Beelen, DW, Rovira, M, Spyridonidis, A, Blaise, D, Bornhauser, M, Karadogan, I, Savani, BN, Nagler, A, Mohty, M, Martin, S, Chevallier, P, Neubauer, A, Damaj, G, Koc, Y, Ganser, A, Collin, M, Yakoub-Agha, I, Ozdogu, H, Araujo, MC, Itala-Remes, M, Orchard, K, Isaksson, C, Bethge, W, Martin, H, Aljurf, M, Faber, E, Caballero, D, Zak, P, Leleu, X, Bay, JO, Rohrlich, PS, Kroger, N, Huynh, A, Schafer-Eckart, K, Milpied, N, Lenhoff, S, Ho, A, Lopez, JLB, Mordini, N, Lioure, B, Halaburda, K, Olivieri, A, Gedde-Dahl, T, Protheroe, R, Tischer, J, Klammer, M, Clausen, J, Potter, V, Ladetto, M, Tilly, H, Deconinck, E, Brecht, A, Muller, LP, Heinicke, T, Carrete, JPT, Bazarbachi, A, Remenyi, P, Rubio, MT, Fanin, R, Perez-Simon, JA, Niels, M, Diez-Martin, JL, Arat, M, Hermine, O, Socie, G, Cornelissen, JJ, Santarone, S, Guyotat, D, Bulabois, CE, Bernasconi, P, Johansson, JE, Vrhovac, R, Greinix, H, Lorenzo, JLL, Apte, S, Craddock, C, Kobbe, G, Zahrani, MA, Dreger, P, Lange, A, Tbakhi, A, Meijer, E, Llamas, CV, Santasusana, JMR, Corradini, P, Benedetti, F, Rambaldi, A, Gandemer, V, Malfuson, JV, Kaare, A, Risitano, A, Petrini, M, Selleri, C, and Wu, DP

Abstract

The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients

Published
2021

16. Lives versus Livelihoods? Perceived economic risk has a stronger association with support for COVID-19 preventive measures than perceived health risk

Author

Nisa, C.F., Bélanger, J.J., Faller, D.G., Buttrick, N.R., Mierau, J.O., Austin, M.M.K., Schumpe, B.M., Sasin, E.M., Agostini, M., Gützkow, B., Kreienkamp, J., Abakoumkin, G., Abdul Khaiyom, J.H., Ahmedi, V., Akkas, H., Almenara, C.A., Atta, M., Bagci, S.C., Basel, S., Kida, E.B., Bernardo, A.B.I., Chobthamkit, P., Choi, H.-S., Cristea, M., Csaba, S., Damnjanović, Kaja, Danyliuk, I., Dash, A., Di Santo, D., Douglas, K.M., Enea, V., Fitzsimons, G., Gheorghiu, A., Gómez, Á., Grzymala-Moszczynska, J., Hamaidia, A., Han, Q., Helmy, M., Hudiyana, J., Jeronimus, B.F., Jiang, D.-Y., Jovanović, V., Kamenov, Ž., Kende, Anna, Keng, S.-L., Kieu, T.T.T., Koc, Y., Kovyazina, K., Kozytska, I., Krause, J., Kruglanski, A.W., Kurapov, A., Kutlaca, M., Lantos, Nora Anna, Lemay, E.P., Lesmana, C.B.J., Louis, W.R., Lueders, A., Malik, N.I., Martinez, A., McCabe, K.O., Mehulić, J., Milla, M.N., Mohammed, I., Molinario, E., Moyano, M., Muhammad, H., Mula, S., Muluk, H., Myroniuk, S., Najafi, R., Nyúl, B., O’Keefe, P.A., Osuna, J.J.O., Osin, E.N., Park, J., Pica, G., Pierro, A., Rees, J., Reitsema, A.M., Resta, E., Rullo, M., Ryan, M.K., Samekin, A., Santtila, P., Selim, Heyla A., Stanton, M.V., Sultana, S., Sutton, R.M., Tseliou, E., Utsugi, A., van Breen, J.A., Van Lissa, C.J., Van Veen, K., vanDellen, M.R., Vázquez, A., Wollast, R., Yeung, V.W.-L., Zand, S., Žeželj, Iris, Zheng, B., Zick, A., Zúñiga, C., Leander, N.P., Nisa, C.F., Bélanger, J.J., Faller, D.G., Buttrick, N.R., Mierau, J.O., Austin, M.M.K., Schumpe, B.M., Sasin, E.M., Agostini, M., Gützkow, B., Kreienkamp, J., Abakoumkin, G., Abdul Khaiyom, J.H., Ahmedi, V., Akkas, H., Almenara, C.A., Atta, M., Bagci, S.C., Basel, S., Kida, E.B., Bernardo, A.B.I., Chobthamkit, P., Choi, H.-S., Cristea, M., Csaba, S., Damnjanović, Kaja, Danyliuk, I., Dash, A., Di Santo, D., Douglas, K.M., Enea, V., Fitzsimons, G., Gheorghiu, A., Gómez, Á., Grzymala-Moszczynska, J., Hamaidia, A., Han, Q., Helmy, M., Hudiyana, J., Jeronimus, B.F., Jiang, D.-Y., Jovanović, V., Kamenov, Ž., Kende, Anna, Keng, S.-L., Kieu, T.T.T., Koc, Y., Kovyazina, K., Kozytska, I., Krause, J., Kruglanski, A.W., Kurapov, A., Kutlaca, M., Lantos, Nora Anna, Lemay, E.P., Lesmana, C.B.J., Louis, W.R., Lueders, A., Malik, N.I., Martinez, A., McCabe, K.O., Mehulić, J., Milla, M.N., Mohammed, I., Molinario, E., Moyano, M., Muhammad, H., Mula, S., Muluk, H., Myroniuk, S., Najafi, R., Nyúl, B., O’Keefe, P.A., Osuna, J.J.O., Osin, E.N., Park, J., Pica, G., Pierro, A., Rees, J., Reitsema, A.M., Resta, E., Rullo, M., Ryan, M.K., Samekin, A., Santtila, P., Selim, Heyla A., Stanton, M.V., Sultana, S., Sutton, R.M., Tseliou, E., Utsugi, A., van Breen, J.A., Van Lissa, C.J., Van Veen, K., vanDellen, M.R., Vázquez, A., Wollast, R., Yeung, V.W.-L., Zand, S., Žeželj, Iris, Zheng, B., Zick, A., Zúñiga, C., and Leander, N.P.

Abstract

This paper examines whether compliance with COVID-19 mitigation measures is motivated by wanting to save lives or save the economy (or both), and which implications this carries to fight the pandemic. National representative samples were collected from 24 countries (N = 25,435). The main predictors were (1) perceived risk to contract coronavirus, (2) perceived risk to suffer economic losses due to coronavirus, and (3) their interaction effect. Individual and country-level variables were added as covariates in multilevel regression models. We examined compliance with various preventive health behaviors and support for strict containment policies. Results show that perceived economic risk consistently predicted mitigation behavior and policy support—and its effects were positive. Perceived health risk had mixed effects. Only two significant interactions between health and economic risk were identified—both positive.

Published
2021

17. Identity integration matters: The case of parents working from home during the COVID-19 health emergency

Author

Manzi, C., Koc, Y., Benet-Martinez, V., Reverberi, E., Manzi C. (ORCID:0000-0002-0742-731X), Reverberi E. (ORCID:0000-0002-3506-2573), Manzi, C., Koc, Y., Benet-Martinez, V., Reverberi, E., Manzi C. (ORCID:0000-0002-0742-731X), and Reverberi E. (ORCID:0000-0002-3506-2573)

Abstract

Since February 2020, the world has faced a health emergency due to the rapid spread of COVID-19. Two of the first measures adopted by most countries to ensure social distancing were the closure of schools and childcare services, and the mandate to work from home. Millions of parents, while facing the threat of the virus infection, suddenly found themselves locked down in their homes managing workload and care load in single “crowded” spaces. This study tested whether relevant identity structures and individual differences (i.e., work-parent identity integration, identification with family, and identification with work) and contextual factors (i.e., work demands, family demands, and housing conditions) predicted parents’ professional, parental, and mental health outcomes during the lockdown. Data collected in April-2020 from 432 Italian parents working from home during the strict lockdown showed that the main predictor of all outcomes is work-parent identity integration. We provide recommendations for how professionals and organizations can support parents working from home due to COVID-19 or in future lockdowns.

Published
2021

18. Outcome of T-cell–replete haploidentical stem cell transplantation improves with time in adults with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Nagler, A., Labopin, M., Koc, Y., Angelucci, E., Tischer, J., Arat, M., Pioltelli, P., Bernasconi, P., Chiusolo, Patrizia, Diez-Martin, J. L., Sanz, J., Ciceri, F., Peric, Z., Giebel, S., Canaani, J., Mohty, M., Chiusolo P. (ORCID:0000-0002-1355-1587), Nagler, A., Labopin, M., Koc, Y., Angelucci, E., Tischer, J., Arat, M., Pioltelli, P., Bernasconi, P., Chiusolo, Patrizia, Diez-Martin, J. L., Sanz, J., Ciceri, F., Peric, Z., Giebel, S., Canaani, J., Mohty, M., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

BACKGROUND: The use of haploidentical hematopoietic cell transplantation (haplo-HCT) with posttransplantation cyclophosphamide prophylaxis is gaining traction in patients with acute lymphoblastic leukemia (ALL). METHODS: The Acute Leukemia Working Party/European Society for Blood and Marrow Transplantation registry was used to evaluate the outcomes of adult patients with ALL who underwent haplo-HCT during 2011 through 2015 and compared them with the outcomes of those who underwent transplantation during 2016 through 2018. RESULTS: The analysis consisted of 195 patients, including 79 who underwent transplantation during 2011 through 2015 and 116 who underwent transplantation during 2016 through 2018. Overall, the 2-year leukemia-free survival and relapse incidence rates were 56.5% and 21%, respectively. The 100-day incidence of grade 2 through 4 acute graft-vs-host disease (GVHD) was 34.5%. The rates of nonrelapse mortality (NRM) and overall survival (OS) were 22.5% and 64.7%, respectively. Patients who underwent transplantation during 2016 through 2018 experienced improved rates of leukemia-free survival (64.9% vs 47.3%; P =.019) and OS (75.5% vs 53.5%; P =.006). Patients who underwent transplantation during 2016 through 2018 developed more grade 2 through 4 acute GVHD (42% vs 26.4%; P =.047). The incidence of relapse, GVHD-free/relapse-free survival, grade 3 and 4 acute GVHD, chronic GVHD, and extensive chronic GVHD did not differ significantly between groups. In multivariate analysis, more recently transplanted patients had a significantly reduced risk of NRM (hazard ratio, 0.44; 95% CI, 0.22-0.89; P =.022) and improved OS (hazard ratio, 0.47; 95% CI, 0.26-0.86; P =.014). A comparable analysis of patients who had acute myeloid leukemia during the same timeframes did not reveal any statistically significant differences in any outcomes. CONCLUSIONS: The outcome of adult patients with ALL who receive posttransplant cyclophosphamide has improved over time, with an imp

Published
2021

19. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT

Author

Ruggeri, A., Labopin, M., Angelucci, E., Blaise, D., Ciceri, F., Koc, Y., Chiusolo, Patrizia, Diez-Martin, J. L., Gulbas, Z., Castagna, L., Bruno, B., Arat, M., Martino, M., Nagler, A., Mohty, M., Chiusolo P. (ORCID:0000-0002-1355-1587), Ruggeri, A., Labopin, M., Angelucci, E., Blaise, D., Ciceri, F., Koc, Y., Chiusolo, Patrizia, Diez-Martin, J. L., Gulbas, Z., Castagna, L., Bruno, B., Arat, M., Martino, M., Nagler, A., Mohty, M., and Chiusolo P. (ORCID:0000-0002-1355-1587)

Abstract

The use of haplo-HCT with posttransplant cyclophosphamide (PT-Cy) is a new standard in the treatment of hematological diseases. A paucity of data exists on risk factors for engraftment failure in haplo-HCT with PT-Cy. We analyzed 1939 adults with acute myeloid leukemia (AML) who received a first haplo-HCT from 2010 to 2019. Status at haplo-HCT was first complete remission (CR1) in 72.5% of patients, secondary AML was reported in 9.9%. Median follow-up was 24.4 months and median age at haplo-HCT was 51 years. Stem cell source was bone marrow (BM) in 42% and peripheral blood stem cell (PBSC) in 58%, and 64% of patients received a myeloablative conditioning (MAC) regimen. Cumulative incidence of primary graft failure (GF) was 6%; GF was reported in 110 patients and 54 died before day +30 with no sign of cell recovery. Overall, 33 patients underwent a second HCT in a median time of 45 days and 13 were alive at last follow-up, the 2-year overall survival (OS) after second HCT being 32.4%. In multivariate analysis, factors independently associated with the risk of nonengraftment were: secondary AML (HR 1.30, p = 0.003), use of RIC (HR 1.22, p < 0.001), and use of BM (HR 1.21, p < 0.001). At 2 years, leukemia-free survival (LFS) and OS for the entire population was 55.2% (95% CI: 52.6–57.6) and 60.9% (95% CI: 58.4–63.3), respectively. Incidence of GF after haplo-HCT with PT-Cy is lower than reported T-cell-depleted haplo-HCT. Optimization of conditioning regimen and graft source should be considered for reducing the risk of GF in haplo-HCT recipients using PT-Cy.

Published
2021

23. Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party

Author

Prata, P.H., Eikema, D.J., Afansyev, B., Bosman, P., Smiers, F., Diez-Martin, J.L., Arrais-Rodrigues, C., Koc, Y., Poir?, X., Sirvent, A., Kr?ger, N., Porta, F., Holter, W., Bloor, A., Jubert, C., Ganser, A., Tanase, A., M?nard, A.L., Pioltelli, P., P?rez-Sim?n, J.A., Ho, A., Aljurf, M., Russell, N., Labussiere-Wallet, H., Kerre, T., Rocha, V., Soci?, G., Risitano, A., Dufour, C., Latour, R.P. de, SAA WP EBMT, Prata, P. H., Eikema, D. -J., Afansyev, B., Bosman, P., Smiers, F., Diez-Martin, J. L., Arrais-Rodrigues, C., Koc, Y., Poire, X., Sirvent, A., Kroger, N., Porta, F., Holter, W., Bloor, A., Jubert, C., Ganser, A., Tanase, A., Menard, A. -L., Pioltelli, P., Perez-Simon, J. A., Ho, A., Aljurf, M., Russell, N., Labussiere-Wallet, H., Kerre, T., Rocha, V., Socie, G., Risitano, A., Dufour, C., and Peffault de Latour, R.

Subjects
medicine.medical_specialty, Transplantation Conditioning, Cyclophosphamide, medicine.medical_treatment, Eltrombopag, Graft vs Host Disease, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Medicine, Humans, Cumulative incidence, Prospective Studies, Aplastic anemia, Prospective cohort study, Transplantation, Univariate analysis, Neutrophil Engraftment, business.industry, Hematopoietic Stem Cell Transplantation, Anemia, Aplastic, Immunosuppression, Hematology, medicine.disease, Europe, chemistry, 030220 oncology & carcinogenesis, Transplantation, Haploidentical, business, 030215 immunology, medicine.drug
Abstract

In Press., In the absence of an HLA-matched donor, the best treatment for acquired aplastic anemia patients refractory to immunosuppression is unclear. We collected and analyzed data from all acquired aplastic anemia patients who underwent a haploidentical transplantation with posttransplant cyclophosphamide in Europe from 2011 to 2017 (n = 33). The cumulative incidence of neutrophil engraftment was 67% (CI95%: 51–83%) at D +28 and was unaffected by age group, stem cell source, ATG use, or Baltimore conditioning regimen. The cumulative incidence of grades II–III acute GvHD was 23% at D +100, and limited chronic GvHD was 10% (0–20) at 2 years, without cases of grade IV acute or extensive chronic GvHD. Two-year overall survival was 78% (64–93), and 2-year graft-versus-host disease-free survival was 63% (46–81). In univariate analysis, the 2-year OS was higher among patients who received the Baltimore conditioning regimen (93% (81–100) versus 64% (41–87), p = 0.03), whereas age group, stem cell source, and ATG use had no effect. Our results using unmanipulated haploidentical transplantation and posttransplant cyclophosphamide for treating refractory AA patients are encouraging, but warrant confirmation in a prospective study with a larger number of patients and longer follow-up.

Published
2019

24. Sex Differences in Self-Construal and in Depressive Symptoms: Predictors of Cross-National Variation

Author

Smith, P.B. Easterbrook, M.J. al-Selim, H. Lun, V.M.C. Koc, Y. Gul, P. Papastylianou, D. Grigoryan, L. Torres, C. Efremova, M. Hassan, B. Ahmad, A.H. al-Bayati, A. Anderson, J. Cross, S.E. Delfino, G.I. Gamsakhurdia, V. Gavreliuc, A. Gavreliuc, D. Gunsoy, C. Hakobjanyan, A. Lay, S. Lopukhova, O. Hu, P. Sunar, D. Texeira, M.L.M. Tripodi, D. Diaz Rivera, P.E. van Osch, Y. Yuki, M. Abbas, A. Ogusu, N. Kwantes, C.T. Diaz-Loving, R. Perez Floriano, L. Chaleeraktrakoon, T. Chobthamkit, P.

Abstract

Sex differences in aspects of independent versus interdependent self-construal and depressive symptoms were surveyed among 5,320 students from 24 nations. Men were found to perceive themselves as more self-contained whereas women perceived themselves as more connected to others. No significant sex differences were found on two further dimensions of self-construal, or on a measure of depressive symptoms. Multilevel modeling was used to test the ability of a series of predictors derived from a social identity perspective and from evolutionary theory to moderate sex differences. Contrary to most prior studies of personality, sex differences in self-construal were larger in samples from nations scoring lower on the Gender Gap Index, and the Human Development Index. Sex differences were also greater in nations with higher pathogen prevalence, higher self-reported religiosity, and in nations with high reported avoidance of settings with strong norms. The findings are discussed in terms of the interrelatedness of self-construals and the cultural contexts in which they are elicited and the distinctiveness of student samples. © The Author(s) 2020.

Published
2020

25. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT

Author

Sanz, J, Galimard, JE, Labopin, M, Afanasyev, B, Angelucci, E, Ciceri, F, Blaise, D, Cornelissen, Jan, Meijer, E, Diez-Martin, JL, Koc, Y, Rovira, M, Castagna, L, Savani, B, Ruggeri, A, Nagler, A, Mohty, M, Sanz, J, Galimard, JE, Labopin, M, Afanasyev, B, Angelucci, E, Ciceri, F, Blaise, D, Cornelissen, Jan, Meijer, E, Diez-Martin, JL, Koc, Y, Rovira, M, Castagna, L, Savani, B, Ruggeri, A, Nagler, A, and Mohty, M

Published
2020

27. Design of a Mini Double-Discharge Centrifugal Pump under Multiphase Flow by CFD and Experimental Verification

Author

Parlak, Z., Kemerli, M., Engin, T., Koc, Y., Parlak, Z, Kemerli, M, Engin, T, Koc, Y, Sakarya Üniversitesi/Mühendislik Fakültesi/Makine Mühendisliği Bölümü, Parlak, Zekeriya, Kemerli, Muaz, and Engin, Tahsin

Subjects
TheoryofComputation_MATHEMATICALLOGICANDFORMALLANGUAGES, lcsh:Mechanical engineering and machinery, ComputingMilieux_PERSONALCOMPUTING, Hardware_INTEGRATEDCIRCUITS, Pump design, Centrifugal pump, Double-outlet pump, CFD, Multiphase flow, lcsh:TJ1-1570, ComputerSystemsOrganization_SPECIAL-PURPOSEANDAPPLICATION-BASEDSYSTEMS, ComputerApplications_COMPUTERSINOTHERSYSTEMS, Mechanics
Abstract

Pumps are irreplaceable products in various systems and processes. Pumps can be manufactured in various size in industry. The mini pumps are commonly used in some household electrical appliances, automobile etc. Some pumping applications is required two outlet ports. The use of two pumps in such a case brings high costs. Instead, pumping on two different lines with a single pump provides both a more compact design and lower cost, if the system is available. In this study, it is aimed to design a single-suction and double-outlet pump by using a single electric motor. For this purpose, a conceptual design for the pump has been proposed and design parameters which have an effect on the pump performance have been determined. Pump performance have been calculated by using the ANSYS Fluent, Computational Fluid Dynamics (CFD) code considering to multiphase flow, and optimization studies have been performed with the determined parameters. The pumps have been obtained by the optimization works have been manufactured and tested to investigate whether the pumps provide the expected operating conditions and performances. Finally, the CFD results have been verified by the tests and the pump provided the expected operating conditions and performances.

Published
2018

29. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

Author

Van Gelder, M, De Wreede, L, Bornhauser, M, Niederwieser, D, Karas, M, Anderson, N, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J, Yakoub-Agha, I, Russell, N, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispizua, A, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, Van Biezen, A, Henseler, A, Schonland, S, Kroger, N, Schetelig, J, Ehninger, G, Jindra, P, Sengeloev, H, Ispizua, A, Arnold, R, Veelken, J, Mufti, G, Milpied, N, Benedetto, B, Schaap, M, Leblond, V, Nikolousis, M, Hallek, M, Passweg, J, Ljungman, P, Masszi, T, Stelljes, M, Browne, P, Glass, B, Espiga, C, Bourhis, J, Roussy, G, Gribben, J, Foa, R, Sierra, J, Mayer, J, Thomson, K, Meijer, E, Blau, W, Holler, E, Bacigalupo, A, Guilhot, F, Carlson, K, Zachee, P, Ifrah, N, Marin, J, Socie, G, Mcquaker, G, Cortelezzi, A, Lenhoff, S, Tischer, J, Irrera, G, Fanin, R, Beguin, Y, Nagler, A, Mackinnon, S, Itala-Remes, M, Deconinck, E, Wulf, G, Corradini, P, Gilleece, M, Wing, B, Peniket, A, Ganser, A, Stuhler, G, Faber, E, Komarnicki, M, Kanz, L, Brune, M, Lamy, T, Sanz, M, Kyrcz-Krzemien, S, Orchard, K, Hunter, A, Sandstedt, A, Fegueux, N, Bandini, G, Robinson, S, Craddock, C, Crawley, C, Griskevicius, L, Bloor, A, Reman, O, Hilgendorf, I, Cannell, P, Ciceri, F, Kalhs, P, Sica, S, Greinix, H, Scime, R, Selleslag, D, Kruger, W, Huynh, A, Einsele, H, Bittenbring, J, Olivieri, A, Hermine, O, Gedde-Dahl, T, Zsiros, J, Guyotat, D, Cordonnier, C, Campos, A, Casini, M, Martinelli, G, Muller, L, Van Imhoff, G, Neubauer, A, Lioure, B, Hamladji, R, Noens, L, Theobald, M, Salvi, F, Ram, R, Poire, X, Or, R, Chalandon, Y, Solano, C, Wilson, K, Santasusana, J, Karakasis, D, Schafer-Eckart, K, Wahlin, A, Mohty, M, Velardi, A, Bron, D, Alegre, A, Cairoli, R, Marotta, G, Lange, A, Narni, F, Fauser, A, Rambaldi, A, Guillerm, G, Heras, I, Snowden, J, Wiktor-Jedrzejczak, W, Schanz, U, Cahn, J, Abecasis, M, Kobbe, G, Salim, R, Junghanss, C, Segel, E, Clement, L, Zak, P, Metzner, B, Espigado, I, Tilly, H, Schroyens, W, Favre, C, Russo, D, Gastl, G, Bay, J, Alessandrino, E, Majolino, I, Bosi, A, Zuckerman, T, Aljurf, M, Thomson, J, Pioltelli, P, Anagnostopoulos, A, Schouten, H, Tholouli, E, Gurman, G, Vural, F, Zver, S, Muniz, S, Afanasyev, B, Pohlreich, D, Hellmann, A, Rosler, W, Martin, S, Apperley, J, Finnegan, D, Renaud, M, Nemet, D, Culligan, D, Castagna, L, Cascavilla, N, Koh, M, Chacon, M, Ozdogu, H, Spencer, A, Llamas, C, Grasso, M, Lopez, S, Benedetti, F, Deeren, D, De Revel, T, Musso, M, Halaburda, K, Sureda, A, Angelucci, E, Diez-Martin, J, Hunter, H, Koc, Y, Bordessoule, D, Fouillard, L, Di Bartolomeo, P, Mazza, P, Novitzky, N, Peschel, C, Lopez, J, Cascon, M, Romeril, K, Schots, R, Brussel, H, Koistinen, P, Arcese, W, Aktan, M, Rodeghiero, F, Butler, A, Pizzuti, M, Melpignano, A, Carella, A, Valcarcel, D, De Toledo Codina, J, Galieni, P, Bader, P, Hahn, Cavanna, L, Sucak, G, Broom, A, Garcia, P, Nicolas-Virelizier, E, Rizzoli, V, Witz, F, Collin, M, Ringhoffer, M, Kansu, E, Martin, H, Moraleda, J, Pranger, D, Greil, R, Bazarbachi, A, Ozturk, M, Fagioli, F, Jantunen, E, Yeshurun, M, Altuntas, F, Bassan, R, Rohrlich, P, Jimenez, S, Glaisner, S, Vinante, O, Clausen, J, Lopez-Jimenez, J, Theunissen, K, Specchia, G, Pavone, V, Krauter, J, Edwards, D, Rifon, J, Everaus, H, Da Prada, G, Wattad, M, Milone, G, Walewski, J, Thieblemont, C, Nasa, G, Duchosal, M, Ferrara, F, Devidas, A, Delmer, A, Degos, L, Van Gelder M., De Wreede L. C., Bornhauser M., Niederwieser D., Karas M., Anderson N. S., Gramatzki M., Dreger P., Michallet M., Petersen E., Bunjes D., Potter M., Beelen D., Cornelissen J. J., Yakoub-Agha I., Russell N. H., Finke J., Schoemans H., Vitek A., Urbano-Ispizua A., Blaise D., Volin L., Chevallier P., Caballero D., Putter H., Van Biezen A., Henseler A., Schonland S., Kroger N., Schetelig J., Ehninger G., Jindra P., Sengeloev H., Russell N., Ispizua A. U., Arnold R., Veelken J. H., Mufti G., Milpied N., Benedetto B., Schaap M., Leblond V., Nikolousis M., Hallek M., Passweg J., Ljungman P., Masszi T., Stelljes M., Browne P., Glass B., Espiga C. R., Bourhis J. H., Roussy G., Gribben J., Foa R., Sierra J., Mayer J., Thomson K., Meijer E., Blau W., Holler E., Bacigalupo A., Guilhot F., Carlson K., Zachee P., Ifrah N., Marin J. R. C., Socie G., McQuaker G., Cortelezzi A., Lenhoff S., Tischer J., Irrera G., Fanin R., Beguin Y., Nagler A., Mackinnon S., Itala-Remes M., Deconinck E., Wulf G., Corradini P., Gilleece M., Wing B., Peniket A., Ganser A., Stuhler G., Faber E., Komarnicki M., Kanz L., Brune M., Lamy T., Sanz M., Kyrcz-Krzemien S., Orchard K., Hunter A., Sandstedt A., Fegueux N., Bandini G., Robinson S., Craddock C., Crawley C., Griskevicius L., Bloor A., Reman O., Hilgendorf I., Cannell P., Ciceri F., Kalhs P., Sica S., Greinix H., Scime R., Selleslag D., Kruger W., Huynh A., Einsele H., Bittenbring J., Olivieri A., Hermine O., Gedde-Dahl T., Zsiros J., Guyotat D., Cordonnier C., Campos A., Casini M., Martinelli G., Muller L. P., Van Imhoff G., Neubauer A., Lioure B., Hamladji R. -M., Noens L., Theobald M., Salvi F., Ram R., Poire X., Or R., Chalandon Y., Solano C., Wilson K., Santasusana J. M. R., Karakasis D., Schafer-Eckart K., Wahlin A., Mohty M., Velardi A., Bron D., Alegre A., Cairoli R., Marotta G., Lange A., Narni F., Fauser A., Rambaldi A., Guillerm G., Heras I., Snowden J., Wiktor-Jedrzejczak W., Schanz U., Cahn J. Y., Abecasis M., Kobbe G., Salim R., Junghanss C., Segel E. K., Clement L., Zak P., Metzner B., Espigado I., Tilly H., Schroyens W., Favre C., Russo D., Gastl G., Bay J. -O., Alessandrino E. P., Majolino I., Bosi A., Zuckerman T., Aljurf M., Thomson J., Pioltelli P., Anagnostopoulos A., Schouten H., Tholouli E., Gurman G., Vural F., Zver S., Muniz S. G., Afanasyev B., Pohlreich D., Hellmann A., Rosler W., Martin S., Apperley J., Finnegan D., Renaud M., Nemet D., Culligan D., Castagna L., Cascavilla N., Koh M., Chacon M. J., Ozdogu H., Spencer A., Llamas C. V., Grasso M., Lopez S. G., Benedetti F., Deeren D., De Revel T., Musso M., Halaburda K., Sureda A., Angelucci E., Diez-Martin J. L., Hunter H., Koc Y., Bordessoule D., Fouillard L., Di Bartolomeo P., Mazza P., Novitzky N., Peschel C., Lopez J. L. B., Cascon M. J. P., Romeril K. R., Schots R., Brussel H., Koistinen P., Arcese W., Aktan M., Rodeghiero F., Butler A., Pizzuti M., Melpignano A., Carella A. M., Valcarcel D., De Toledo Codina J. S., Galieni P., Bader P., Cavanna L., Sucak G., Broom A. J. M., Garcia P. G., Nicolas-Virelizier E., Rizzoli V., Witz F., Collin M., Ringhoffer M., Kansu E., Martin H., Moraleda J., Pranger D., Greil R., Bazarbachi A., Ozturk M., Fagioli F., Jantunen E., Yeshurun M., Altuntas F., Bassan R., Rohrlich P. -S., Jimenez S., Glaisner S., Vinante O., Clausen J., Lopez-Jimenez J., Theunissen K., Specchia G., Pavone V., Krauter J., Edwards D., Rifon J., Everaus H., Da Prada G. A., Wattad M., Milone G., Walewski J., Thieblemont C., Nasa G. L., Duchosal M., Ferrara F., Devidas A., Delmer A., Degos L., Van Gelder, M, De Wreede, L, Bornhauser, M, Niederwieser, D, Karas, M, Anderson, N, Gramatzki, M, Dreger, P, Michallet, M, Petersen, E, Bunjes, D, Potter, M, Beelen, D, Cornelissen, J, Yakoub-Agha, I, Russell, N, Finke, J, Schoemans, H, Vitek, A, Urbano-Ispizua, A, Blaise, D, Volin, L, Chevallier, P, Caballero, D, Putter, H, Van Biezen, A, Henseler, A, Schonland, S, Kroger, N, Schetelig, J, Ehninger, G, Jindra, P, Sengeloev, H, Ispizua, A, Arnold, R, Veelken, J, Mufti, G, Milpied, N, Benedetto, B, Schaap, M, Leblond, V, Nikolousis, M, Hallek, M, Passweg, J, Ljungman, P, Masszi, T, Stelljes, M, Browne, P, Glass, B, Espiga, C, Bourhis, J, Roussy, G, Gribben, J, Foa, R, Sierra, J, Mayer, J, Thomson, K, Meijer, E, Blau, W, Holler, E, Bacigalupo, A, Guilhot, F, Carlson, K, Zachee, P, Ifrah, N, Marin, J, Socie, G, Mcquaker, G, Cortelezzi, A, Lenhoff, S, Tischer, J, Irrera, G, Fanin, R, Beguin, Y, Nagler, A, Mackinnon, S, Itala-Remes, M, Deconinck, E, Wulf, G, Corradini, P, Gilleece, M, Wing, B, Peniket, A, Ganser, A, Stuhler, G, Faber, E, Komarnicki, M, Kanz, L, Brune, M, Lamy, T, Sanz, M, Kyrcz-Krzemien, S, Orchard, K, Hunter, A, Sandstedt, A, Fegueux, N, Bandini, G, Robinson, S, Craddock, C, Crawley, C, Griskevicius, L, Bloor, A, Reman, O, Hilgendorf, I, Cannell, P, Ciceri, F, Kalhs, P, Sica, S, Greinix, H, Scime, R, Selleslag, D, Kruger, W, Huynh, A, Einsele, H, Bittenbring, J, Olivieri, A, Hermine, O, Gedde-Dahl, T, Zsiros, J, Guyotat, D, Cordonnier, C, Campos, A, Casini, M, Martinelli, G, Muller, L, Van Imhoff, G, Neubauer, A, Lioure, B, Hamladji, R, Noens, L, Theobald, M, Salvi, F, Ram, R, Poire, X, Or, R, Chalandon, Y, Solano, C, Wilson, K, Santasusana, J, Karakasis, D, Schafer-Eckart, K, Wahlin, A, Mohty, M, Velardi, A, Bron, D, Alegre, A, Cairoli, R, Marotta, G, Lange, A, Narni, F, Fauser, A, Rambaldi, A, Guillerm, G, Heras, I, Snowden, J, Wiktor-Jedrzejczak, W, Schanz, U, Cahn, J, Abecasis, M, Kobbe, G, Salim, R, Junghanss, C, Segel, E, Clement, L, Zak, P, Metzner, B, Espigado, I, Tilly, H, Schroyens, W, Favre, C, Russo, D, Gastl, G, Bay, J, Alessandrino, E, Majolino, I, Bosi, A, Zuckerman, T, Aljurf, M, Thomson, J, Pioltelli, P, Anagnostopoulos, A, Schouten, H, Tholouli, E, Gurman, G, Vural, F, Zver, S, Muniz, S, Afanasyev, B, Pohlreich, D, Hellmann, A, Rosler, W, Martin, S, Apperley, J, Finnegan, D, Renaud, M, Nemet, D, Culligan, D, Castagna, L, Cascavilla, N, Koh, M, Chacon, M, Ozdogu, H, Spencer, A, Llamas, C, Grasso, M, Lopez, S, Benedetti, F, Deeren, D, De Revel, T, Musso, M, Halaburda, K, Sureda, A, Angelucci, E, Diez-Martin, J, Hunter, H, Koc, Y, Bordessoule, D, Fouillard, L, Di Bartolomeo, P, Mazza, P, Novitzky, N, Peschel, C, Lopez, J, Cascon, M, Romeril, K, Schots, R, Brussel, H, Koistinen, P, Arcese, W, Aktan, M, Rodeghiero, F, Butler, A, Pizzuti, M, Melpignano, A, Carella, A, Valcarcel, D, De Toledo Codina, J, Galieni, P, Bader, P, Hahn, Cavanna, L, Sucak, G, Broom, A, Garcia, P, Nicolas-Virelizier, E, Rizzoli, V, Witz, F, Collin, M, Ringhoffer, M, Kansu, E, Martin, H, Moraleda, J, Pranger, D, Greil, R, Bazarbachi, A, Ozturk, M, Fagioli, F, Jantunen, E, Yeshurun, M, Altuntas, F, Bassan, R, Rohrlich, P, Jimenez, S, Glaisner, S, Vinante, O, Clausen, J, Lopez-Jimenez, J, Theunissen, K, Specchia, G, Pavone, V, Krauter, J, Edwards, D, Rifon, J, Everaus, H, Da Prada, G, Wattad, M, Milone, G, Walewski, J, Thieblemont, C, Nasa, G, Duchosal, M, Ferrara, F, Devidas, A, Delmer, A, Degos, L, Van Gelder M., De Wreede L. C., Bornhauser M., Niederwieser D., Karas M., Anderson N. S., Gramatzki M., Dreger P., Michallet M., Petersen E., Bunjes D., Potter M., Beelen D., Cornelissen J. J., Yakoub-Agha I., Russell N. H., Finke J., Schoemans H., Vitek A., Urbano-Ispizua A., Blaise D., Volin L., Chevallier P., Caballero D., Putter H., Van Biezen A., Henseler A., Schonland S., Kroger N., Schetelig J., Ehninger G., Jindra P., Sengeloev H., Russell N., Ispizua A. U., Arnold R., Veelken J. H., Mufti G., Milpied N., Benedetto B., Schaap M., Leblond V., Nikolousis M., Hallek M., Passweg J., Ljungman P., Masszi T., Stelljes M., Browne P., Glass B., Espiga C. R., Bourhis J. H., Roussy G., Gribben J., Foa R., Sierra J., Mayer J., Thomson K., Meijer E., Blau W., Holler E., Bacigalupo A., Guilhot F., Carlson K., Zachee P., Ifrah N., Marin J. R. C., Socie G., McQuaker G., Cortelezzi A., Lenhoff S., Tischer J., Irrera G., Fanin R., Beguin Y., Nagler A., Mackinnon S., Itala-Remes M., Deconinck E., Wulf G., Corradini P., Gilleece M., Wing B., Peniket A., Ganser A., Stuhler G., Faber E., Komarnicki M., Kanz L., Brune M., Lamy T., Sanz M., Kyrcz-Krzemien S., Orchard K., Hunter A., Sandstedt A., Fegueux N., Bandini G., Robinson S., Craddock C., Crawley C., Griskevicius L., Bloor A., Reman O., Hilgendorf I., Cannell P., Ciceri F., Kalhs P., Sica S., Greinix H., Scime R., Selleslag D., Kruger W., Huynh A., Einsele H., Bittenbring J., Olivieri A., Hermine O., Gedde-Dahl T., Zsiros J., Guyotat D., Cordonnier C., Campos A., Casini M., Martinelli G., Muller L. P., Van Imhoff G., Neubauer A., Lioure B., Hamladji R. -M., Noens L., Theobald M., Salvi F., Ram R., Poire X., Or R., Chalandon Y., Solano C., Wilson K., Santasusana J. M. R., Karakasis D., Schafer-Eckart K., Wahlin A., Mohty M., Velardi A., Bron D., Alegre A., Cairoli R., Marotta G., Lange A., Narni F., Fauser A., Rambaldi A., Guillerm G., Heras I., Snowden J., Wiktor-Jedrzejczak W., Schanz U., Cahn J. Y., Abecasis M., Kobbe G., Salim R., Junghanss C., Segel E. K., Clement L., Zak P., Metzner B., Espigado I., Tilly H., Schroyens W., Favre C., Russo D., Gastl G., Bay J. -O., Alessandrino E. P., Majolino I., Bosi A., Zuckerman T., Aljurf M., Thomson J., Pioltelli P., Anagnostopoulos A., Schouten H., Tholouli E., Gurman G., Vural F., Zver S., Muniz S. G., Afanasyev B., Pohlreich D., Hellmann A., Rosler W., Martin S., Apperley J., Finnegan D., Renaud M., Nemet D., Culligan D., Castagna L., Cascavilla N., Koh M., Chacon M. J., Ozdogu H., Spencer A., Llamas C. V., Grasso M., Lopez S. G., Benedetti F., Deeren D., De Revel T., Musso M., Halaburda K., Sureda A., Angelucci E., Diez-Martin J. L., Hunter H., Koc Y., Bordessoule D., Fouillard L., Di Bartolomeo P., Mazza P., Novitzky N., Peschel C., Lopez J. L. B., Cascon M. J. P., Romeril K. R., Schots R., Brussel H., Koistinen P., Arcese W., Aktan M., Rodeghiero F., Butler A., Pizzuti M., Melpignano A., Carella A. M., Valcarcel D., De Toledo Codina J. S., Galieni P., Bader P., Cavanna L., Sucak G., Broom A. J. M., Garcia P. G., Nicolas-Virelizier E., Rizzoli V., Witz F., Collin M., Ringhoffer M., Kansu E., Martin H., Moraleda J., Pranger D., Greil R., Bazarbachi A., Ozturk M., Fagioli F., Jantunen E., Yeshurun M., Altuntas F., Bassan R., Rohrlich P. -S., Jimenez S., Glaisner S., Vinante O., Clausen J., Lopez-Jimenez J., Theunissen K., Specchia G., Pavone V., Krauter J., Edwards D., Rifon J., Everaus H., Da Prada G. A., Wattad M., Milone G., Walewski J., Thieblemont C., Nasa G. L., Duchosal M., Ferrara F., Devidas A., Delmer A., and Degos L.

Abstract

Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.

Published
2017

31. Topology-Driven Performance Analysis of Power Grids

Author

Çetinay Iyicil, H., Koc, Y., Kuipers, F.A., Van Mieghem, P.F.A., Palensky, Peter, Cvetković, Miloš, and Keviczky, Tamás

Subjects
Electric power transmission, Computer science, Redundancy (engineering), Complete graph, Path graph, Electric power, AC power, Topology, Voltage drop, Voltage
Abstract

Direct connections between nodes usually result in efficient transmission in networks. Such electric power transmission is governed by physical laws, and an assessment purely based on direct connections between nodes and shortest paths may not capture the operation of power grids. Motivated by these facts, in this chapter, we investigate the relation between the electric power transmission in a power grid and its underlying topology. Initially, we focus on synthetic power grids whose underlying topology can be structured as either a path or a complete graph. We analytically compute the impact of electric power transmission on link flows under the normal operation and under a link failure contingency using the linearised DC power flow equations. Subsequently, in various other graph types, we provide empirical results on the link flow, the voltage magnitude and the total active power loss in power grids using the nonlinear AC power flow equations. Our results show that in a path graph, as an assessment based on shortest paths holds, however, the electric power transmission can lead to substantial amount of link flows, active power loss and voltage drops, especially in large path graphs. On the other hand, adding few links to a path graph could significantly improve those performance indicators of power grids, but at a cost: the resulting meshed topology decreases the control over power grids as a direct assessment between the shortest paths and the electric power transformation is lost. Additionally, a meshed topology with loops increases the redundancy in the design to ensure a safe operation under a link failure contingency.

Published
2019

34. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation

Author

Raj, K., Eikema, D.J., McLornan, D.P., Olavarria, E., Blok, H.J., Bregante, S., Ciceri, F., Passweg, J., Ljungman, P., Schaap, N.P., Carlson, K., Zuckerman, T., Wreede, L.C. de, Volin, L., Koc, Y., Diez-Martin, J.L., Brossart, P., Wolf, D., Blaise, D., Bartolomeo, P.D., Vitek, A., Robin, M., Yakoub-Agha, I., Chalandon, Y., Kroger, N., Raj, K., Eikema, D.J., McLornan, D.P., Olavarria, E., Blok, H.J., Bregante, S., Ciceri, F., Passweg, J., Ljungman, P., Schaap, N.P., Carlson, K., Zuckerman, T., Wreede, L.C. de, Volin, L., Koc, Y., Diez-Martin, J.L., Brossart, P., Wolf, D., Blaise, D., Bartolomeo, P.D., Vitek, A., Robin, M., Yakoub-Agha, I., Chalandon, Y., and Kroger, N.

Abstract

Contains fulltext : 202803.pdf (publisher's version ) (Open Access), This analysis included 56 myelofibrosis (MF) patients transplanted from family mismatched donor between 2009 and 2015 enrolled in the European Society for Blood and Marrow Transplantation database. The median age was 57years (range, 38 to 72); 75% had primary MF and 25% had secondary MF. JAK2 V617F was mutated in 61%. Donors were HLA mismatched at 2 or more loci. Stem cells were sourced from bone marrow in 66% and peripheral blood in 34%. The median CD34(+) cell dose was 4.8x10(6)/kg (range, 1.7 to 22.9; n=43). Conditioning was predominantly myeloablative in 70% and reduced intensity in the remainder. Regimens were heterogeneous with thiotepa, busulfan, fludarabine, and post-transplant cyclophosphamide used in 59%. The incidence of neutrophil engraftment by 28days was 82% (range, 70% to 93%), at a median of 21days (range, 19 to 23). At 2years the cumulative incidence of primary graft failure was 9% (95% CI 1% to 16%) and secondary graft failure was 13% (95% CI 4% to 22%). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II to IV and III to IV was 28% (95% CI 16% to 40%) and 9% (95% CI 2% to 17%) at 100days. The cumulative incidence of chronic GVHD at 1 year was 45% (95% CI 32% to 58%), but the cumulative incidence of death without chronic GVHD by 1 year was 20% (95% CI 10% to 31%). With a median follow-up of 32 months, the 1- and 2-year overall survival was 61% (95% CI 48% to 74%) and 56% (95% CI 41% to 70%), respectively. The 1- and 2- year progression-free survival was 58% (95% CI 45% to 71%) and 43% (95% CI 28% to 58%), respectively, with a 2-year cumulative incidence of relapse of 19% (95% CI 7% to 31%). The 2-year nonrelapse mortality was 38% (95% CI 24% to 51%). This retrospective study of MF allo-SCT using family mismatched donors demonstrated feasibility of the approach, timely neutrophil engraftment in over 80% of cases, and acceptable overall and progression-free survival rates with relapse rates not dissimilar to the unrelated don

Published
2019

35. Topology-Driven Performance Analysis of Power Grids

Author

Çetinay Iyicil, H. (author), Koc, Y. (author), Kuipers, F.A. (author), Van Mieghem, P.F.A. (author), Çetinay Iyicil, H. (author), Koc, Y. (author), Kuipers, F.A. (author), and Van Mieghem, P.F.A. (author)

Abstract

Direct connections between nodes usually result in efficient transmission in networks. Such electric power transmission is governed by physical laws, and an assessment purely based on direct connections between nodes and shortest paths may not capture the operation of power grids. Motivated by these facts, in this chapter, we investigate the relation between the electric power transmission in a power grid and its underlying topology. Initially, we focus on synthetic power grids whose underlying topology can be structured as either a path or a complete graph. We analytically compute the impact of electric power transmission on link flows under the normal operation and under a link failure contingency using the linearised DC power flow equations. Subsequently, in various other graph types, we provide empirical results on the link flow, the voltage magnitude and the total active power loss in power grids using the nonlinear AC power flow equations. Our results show that in a path graph, as an assessment based on shortest paths holds, however, the electric power transmission can lead to substantial amount of link flows, active power loss and voltage drops, especially in large path graphs. On the other hand, adding few links to a path graph could significantly improve those performance indicators of power grids, but at a cost: the resulting meshed topology decreases the control over power grids as a direct assessment between the shortest paths and the electric power transformation is lost. Additionally, a meshed topology with loops increases the redundancy in the design to ensure a safe operation under a link failure contingency., Network Architectures and Services, Embedded and Networked Systems

Published
2019
Full Text
View/download PDF

36. Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting

Author

Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D. -J., Bonini, C., Chabannon, C., van der Werf, S., van Biezen, A., de Wreede, L. C., Crucitti, L., Vago, L., Merluzzi, M., Massei, M. S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, Franco, Ciceri, F., Toubert, A., Velardi, A., Locatelli F. (ORCID:0000-0002-7976-3654), Bondanza, A., Ruggeri, L., Noviello, M., Eikema, D. -J., Bonini, C., Chabannon, C., van der Werf, S., van Biezen, A., de Wreede, L. C., Crucitti, L., Vago, L., Merluzzi, M., Massei, M. S., Veelken, H., Koc, Y., Bader, P., Gruhn, B., Locatelli, Franco, Ciceri, F., Toubert, A., Velardi, A., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

HLA-haploidentical haematopoietic stem cell transplantation (haplo-HSCT) is increasingly offered to patients with high-risk acute leukaemia. Unfortunately, haplo-HSCT is followed by a delayed immunoreconstitution. The aim of this EBMT registry study was to explore the clinical impact of lymphocyte subset counts after haplo-HSCT. We considered 144 leukaemic patients transplanted in the period 2001–2012. Pre-transplantation clinical variables and differential immune-cell counts (CD3, CD4, CD8 T cells, NK and B cells) measured before day 100 were evaluated for their capacity to predict overall survival, relapse mortality or non-relapse mortality (NRM). Negative prognostic factors for overall survival were advanced disease state at transplantation, host age and CMV seropositivity. Higher CD3, CD4 and CD8 counts were associated with a better overall survival and a lower NRM. Strikingly, when tested in multivariable analysis, higher CD3 and CD8 counts were still significantly associated with a lower NRM. These results indicate that an accelerated T-cell reconstitution correlates with less transplantation mortality, likely due to the protective role of T cells against viral infections. This observation suggests that CD8+ T-cell counts should be investigated as surrogate biomarkers of outcome in prospective haplo-HSCT trials.

Published
2019

38. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Author

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N, CLL subcommittee, and Chronic Malignancies Working Party of the EBMT

Published
2018

39. HOW TO SELECT DONOR, STEM CELL SOURCE, AND CONDITIONING REGIMEN FOR HAPLOIDENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR LYMPHOMA: A REPORT OF THE EBMT LWP

Author

Bazarbachi, A., primary, Boumendil, A., additional, Finel, H., additional, Castagna, L., additional, Dominietto, A., additional, Blaise, D., additional, Diez-Martin, J., additional, Tischer, J., additional, Gülbas, Z., additional, Labussière Wallet, H., additional, Lopez Corral, L., additional, Mohty, M., additional, Koc, Y., additional, Yakoub-Agha, I., additional, Schmid, C., additional, el Cheikh, J., additional, Arat, M., additional, Forcade, E., additional, Dreger, P., additional, Rocha, V., additional, Gutiérrez García, G., additional, Chalandon, Y., additional, Ferra, C., additional, Orvain, C., additional, Robinson, S., additional, Montoto, S., additional, and Sureda, A., additional

Published
2019
Full Text
View/download PDF

40. S114 POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT

Author

Nagler, A., primary, Labopin, M., additional, Ruggeri, A., additional, Ciceri, F., additional, Sanz, J., additional, Angelucci, E., additional, Koc, Y., additional, Gülbas, Z., additional, Arcese, W., additional, Tischer, J., additional, Pioltelli, P., additional, Ozdogu, H., additional, Afanasyev, B., additional, Wu, D., additional, Arat, M., additional, Peric, Z., additional, Giebel, S., additional, and Mohty, M., additional

Published
2019
Full Text
View/download PDF

41. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

Author

Ruggeri, A. (Annelisa), Labopin, M. (Myriam), Bacigalupo, A. (Andrea), Afanasyev, B. (Boris), Cornelissen, J.J. (Jan), Elmaagacli, A. (Ahmet), Itälä Remes, M. (Maija), Blaise, D. (Didier), Meijer, E. (Ellen), Koc, Y. (Yener), Milpied, N., Schouten, H. (Harry), Kroeger, N. (Nicolaus), Mohty, M. (Mohamad), Nagler, A. (Arnon), Ruggeri, A. (Annelisa), Labopin, M. (Myriam), Bacigalupo, A. (Andrea), Afanasyev, B. (Boris), Cornelissen, J.J. (Jan), Elmaagacli, A. (Ahmet), Itälä Remes, M. (Maija), Blaise, D. (Didier), Meijer, E. (Ellen), Koc, Y. (Yener), Milpied, N., Schouten, H. (Harry), Kroeger, N. (Nicolaus), Mohty, M. (Mohamad), and Nagler, A. (Arnon)

Abstract

Background: Experience using post-transplant cyclophosphamide (PT-Cy) as graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation (HSCT) from matched sibling donors (MSD) or unrelated donors (UD) is limited and with controversial results. The study aim was to evaluate PT-Cy as GVHD prophylaxis post-HSCT from MSD and UD transplants. We analyzed 423 patients with acute leukemia who received PT-Cy alone or in combination with other immunosuppressive (IS) drugs as GVHD prophylaxis. Seventy-eight patients received PT-Cy alone (group 1); 204 received PT-Cy in combination with one IS drug - cyclosporine-A (CSA) or methotrexate (MTX) or mycophenolate-mofetil (MMF) (group 2), while 141 patients received PT-Cy in combination with two IS drugs - CSA + MTX or CSA + MMF (group 3). Transplants were performed from 2007 to 2015 and median follow-up was 20 months. Results: Probability of overall survival (OS) at 2 years was 50, 52.2, and 62.4%, for the three groups, respectively, p = 0.06. In multivariate analysis, in comparison to PT-Cy alone, the addition of two IS drugs was associated with reduced risk of extensive cGVHD (HR 0.25, p = 0.02). Use of bone marrow (BM) and anti-thymocyte globulin were independently associated with reduced risk of extensive cGVHD. Prognostic factors for non-relapse mortality (NRM) were the addition of two IS drugs to PT-Cy (HR 0.35, p = 0.04), diagnosis of AML, disease status at transplant, and patient CMV serology. Factors associated with increased OS were the use of PT-Cy with two IS drugs (HR 0.49, p = 0.02), AML, and disease status at transplant. Conclusion: For GVHD prophylaxis in MSD and UD HSCT, the addition of IS drugs to PT-Cy enhances its effect and reduces the risk of severe cGVHD, reducing mortality and improving survival.

Published
2018
Full Text
View/download PDF

42. iObjectify: Self- and other-objectification on Grindr, a geosocial networking application designed for men who have sex with men

Author

Anderson, JR, Holland, E, Koc, Y, Haslam, N, Anderson, JR, Holland, E, Koc, Y, and Haslam, N

Abstract

Grindr is a smartphone application for men who have sex with men (MSM). Despite its reputation as a ‘hook‐up app’, little is known about its users' self‐presentation strategies and how this relates to objectification. This article explores objectification on Grindr. The results of Study 1 showed that Grindr users objectified other men more than non‐Grindr users. A content analysis of 1400 Grindr profiles in Study 2 showed that profile pictures with objectifying content were related to searching for sexual encounters. Finally, a survey of Grindr users in Study 3 revealed that objectification processes and sexualized profile pictures were related to some objectification‐relevant online behaviors (e.g., increased use of Grindr, discussion of HIV status). Interestingly, the presence of body focused profile content was more related to sexual orientation disclosure (not being ‘out’) than to objectification. This article presents evidence that Grindr usage and online presentation are related to objectification processes.

Published
2018

43. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

Author

Ruggeri, A, Labopin, M, Bacigalupo, A, Afanasyev, B, Cornelissen, Jan, Elmaagacli, A, Itala-Remes, M, Blaise, D, Meijer, E, Koc, Y, Milpied, N, Schouten, HC, Kroeger, N, Mohty, M, Nagler, A, Ruggeri, A, Labopin, M, Bacigalupo, A, Afanasyev, B, Cornelissen, Jan, Elmaagacli, A, Itala-Remes, M, Blaise, D, Meijer, E, Koc, Y, Milpied, N, Schouten, HC, Kroeger, N, Mohty, M, and Nagler, A

Published
2018

44. CKD GENERAL AND CLINICAL EPIDEMIOLOGY 2

Author

Davids, M. R., Marais, N., Jacobs, J., Cohen, E., Krause, I., Goldberg, E., Garty, M., Dursun, B., Sahan, Y., Tanriverdi, H., Rota, S., Uslu, S., Senol, H., Minutolo, R., Gabbai, F. B., Agarwal, R., Chiodini, P., Borrelli, S., Stanzione, G., Nappi, F., Bellizzi, V., Conte, G., Nicola, L. D., J. V., De, Johnson, S., Fremeaux Bacchi, V., Ardissino, G., Ariceta, G., Beauchamp, J., Cohen, D., Greenbaum, L. A., Ogawa, M., Schaefer, F., Licht, C., Scalzotto, E., Nalesso, F., Zaglia, T., Corradi, V., Neri, M., Martino, F., Zanella, M., Brendolan, A., Mongillo, M., Ronco, C., Chinnappa, S., Mooney, A., A. M., El, Y. K., Tu, Tan, L. B., Jung, J. Y., Kim, A. J., Ro, H., Lee, C., Chang, J. H., Lee, H. H., Chung, W., Clarke, A. L., Young, H. M., Hull, K. L., Hudson, N., Burton, J. O., Smith, A. C., Marx, S., Petrilla, A., Filipovic, I., Lee, W. C., Meijers, B., Poesen, R., Storr, M., Claes, K., Kuypers, D., Evenepoel, P., Aukland, M., Betriu, A., Martinez Alonso, M., Arcidiacono, M. V., Cannata Andia, J., Pascual, J., Valdivielso, J. M., Fernandez Giraldez, E., Kingswood, J. C., Zonnenberg, B., Sauter, M., Zakar, G., Biro, B., Besenczi, B., Varga, A., Pekacs, P., Pizzini, P., Pisano, A., Leonardis, D., Panuccio, V., Cutrupi, S., Tripepi, G., Mallamaci, F., Zoccali, C., Arnold, J., Baharani, J., Rayner, H., B. H., So, Blackwell, S., Jardine, A. G., Macgregor, M. S., Cunha, C., Barreto, P., Pereira, S., Ventura, A., Mota, M., Seabra, J., Sakaguchi, T., Kobayashi, S., Yano, T., Yoshimoto, W., Bancu, I., Bastons, J. B., Escayola, M. C., Vallespin, E. V., Poblet, M. B., Luque, D. M., Fabregas, M. P., Chen, J., Chen, S., Chang, J., Hwang, S., Chen, H., Ahbap, E., Kara, E., Basturk, T., Sahutoglu, T., Koc, Y., Sakaci, T., Sevinc, M., Akgol, C., Ozagari, A. A., Unsal, A., Minami, S., Hesaka, A., Yamaguchi, S., Iwahashi, E., Sakai, S., Fujimoto, T., Sasaki, K., Fujita, Y., Yokoyama, K., Marks, A., Fluck, N., Prescott, G., Robertson, L., Smith, W. C., Black, C., Ohsawa, M., Fujioka, T., Omori, S., Isurugi, T., Tanno, K., Onoda, T., Omama, S., Ishibashi, Y., Makita, S., Okayama, A., Garland, J. S., Simpson, C. S., Metangi, M. F., Parfrey, B., Johri, A. M., Sloan, L., Mcauley, J., Cunningham, R., Mullan, R., Quinn, M., Harron, C., Chiu, H., Murphy Burke, D., Werb, R., Jung, B., Chan Yan, C., Duncan, J., Forzley, B., Lowry, R., Hargrove, G., Carson, R., Levin, A., Karim, M., Reznik, E. V., G. I. V., Rollino, C., Troiano, M., Bagatella, M., Liuzzo, C., Quarello, F., Roccatello, D., Blaslov, K., Bulum, T., Prkacin, I., Duvnjak, L., Heleniak, Z., Cieplinska, M., Szychlinski, T., Pryczkowska, M., Bartosinska, E., Wiatr, H., Kotlowska, H., Tylicki, L., Rutkowski, B., Song, Y. R., Kim, S. G., Kim, H. J., Noh, J. W., Tong, A., Jesudason, S., Craig, J. C., Winkelmayer, W. C., Hung, P. H., Huang, Y. T., Hsiao, C. Y., Sung, P. S., Guo, H. R., Tsai, K. J., Wu, C., Su, S., Kao, S., Lu, K., Lin, Y., Lin, W., Lee, H., Cheng, M., Wang, W., Yang, L., Wang, M., Lela, I. V., Sekoranja, M., Poljicanin, T., Karanovic, S., Abramovic, M., Matijevic, V., Stipancic, Z., Leko, N., Cvitkovic, A., Dika, Z., Kos, J., Laganovic, M., Grollman, A. P., Jelakovic, B., Dryl Rydzynska, T., Prystacki, T., Malyszko, J., Trifiro', Gianluca, Sultana, J., Giorgianni, F., Ingrasciotta, Y., Muscianisi, M., Tari, D. U., Perrotta, M., Buemi, Michele, Canale, V., Arcoraci, Vincenzo, Santoro, Domenico, Rizzo, M., Iheanacho, I., Van, F. E., Goldsmith, D., Grandtnerova, B., Beratsova, Z., Cervenˇova, M., Cˇervenˇ, J., Markech, M., Stefanikova, A., Engelen, W., Elseviers, M., Gheuens, E., Colson, C., Muyshondt, I., and Daelemans, R.

Subjects
Transplantation, medicine.medical_specialty, business.industry, urologic and male genital diseases, medicine.disease, Gastroenterology, female genital diseases and pregnancy complications, Nephrology, Internal medicine, mental disorders, Medicine, Stage (cooking), Metabolic syndrome, business, Kidney disease
Published
2014
Full Text
View/download PDF

45. Haploidentical transplant in patients with myelodysplastic syndrome

Author

Robin, M., Porcher, R., Ciceri, F., Lint, M.T. van, Santarone, S., Ehninger, G., Blaise, D., Gullbas, Z., Gonzales Muniz, S., Michallet, M., Velardi, A., Koster, L, Maertens, J., Sierra, J., Selleslag, D., Radujkovic, A., Diez-Martin, J.L., Kanz, L., Arroyo, C.H., Niederwieser, D., Huang, H., McDonald, A., Witte, T.J. de, Koc, Y., Kroger, N., Robin, M., Porcher, R., Ciceri, F., Lint, M.T. van, Santarone, S., Ehninger, G., Blaise, D., Gullbas, Z., Gonzales Muniz, S., Michallet, M., Velardi, A., Koster, L, Maertens, J., Sierra, J., Selleslag, D., Radujkovic, A., Diez-Martin, J.L., Kanz, L., Arroyo, C.H., Niederwieser, D., Huang, H., McDonald, A., Witte, T.J. de, Koc, Y., and Kroger, N.

Abstract

Item does not contain fulltext, The only curative treatment in patients with intermediate or high-risk myelodysplastic syndrome (MDS) is allogeneic hematopoietic stem cell transplantation (HSCT), which usually results in a long-term, disease-free survival rate of between 30% and 50%, depending on the disease risk and the type of donor. In patients without an HLA-matched sibling donor, a family haploidentical donor is an alternative option. The present study reports the European Group for Blood and Marrow Transplantation activity for haploidentical transplantation in MDS patients. A total of 228 patients transplanted from a mismatched HLA-related donor between 2007 and 2014 were studied. The median age at transplant was 56 years. Eighty-four (37%) patients had MDS transformed into acute myeloid leukemia at the time of transplant. Ex vivo T-cell depletion was used in 34 patients. One hundred ninety-four patients received a T-cell replete transplant and 102 patients received posttransplant cyclophosphamide (PT-CY) as graft-versus-host disease (GVHD) prophylaxis. The cumulative incidences of acute and chronic GVHD in PT-CY vs other patients were 25% vs 37% and 37% vs 24%, respectively. The cumulative incidence of nonrelapse mortality was 55% in patients who did not receive PT-CY (no PT-CY) and 41% in patients who did receive PT-CY. Three-year overall survival was 28% in no PT-CY patients and 38% in PT-CY patients. In multivariable analysis, the main risk factors were the intensity of the conditioning regimen and the use of PT-CY. In conclusion, the outcomes of MDS patients who received an haploidentical transplant are close to the results other transplantations from HLA-mismatched donors with approximately one-third of patients alive and free of disease 3 years after transplant, and the use of PT-CY may improve their outcomes.

Published
2017

46. Distributed monitoring for the prevention of cascading failures in operational power grids

Author

Warnier, Martijn (author), Dulman, S.O. (author), Koc, Y. (author), Pauwels, E.J.E.M. (author), Warnier, Martijn (author), Dulman, S.O. (author), Koc, Y. (author), and Pauwels, E.J.E.M. (author)

Abstract

Electrical power grids are vulnerable to cascading failures that can lead to large blackouts. The detection and prevention of cascading failures in power grids are important problems. Currently, grid operators mainly monitor the states (loading levels) of individual components in a power grid. The complex architecture of a power grid, with its many interdependencies, makes it difficult to aggregate the data provided by local components in a meaningful and timely manner. Indeed, monitoring the resilience of an operational power grid to cascading failures is a major challenge. This paper attempts to address this challenge. It presents a robustness metric based on the topology and operative state of a power grid to quantify the robustness of the grid. Also, it presents a distributed computation method with self-stabilizing properties that can be used for near real-time monitoring of grid robustness. The research thus provides insights into the resilience of a dynamic operational power grid to cascading failures during real-time in a manner that is both scalable and robust. Computations are pushed to the power grid network, making the results available at each node and enabling automated distributed control mechanisms to be implemented., System Engineering

Published
2017
Full Text
View/download PDF

47. Experimental and theoretical study

Author

Tasli, PT, Bayrakdar, A, Karakus, OO, Kart, HH, and Koc, Y

Abstract

In this study, three novel Schiff base compounds such as N-(4-nitrobenzyl)-4-methyl bromo aniline (1a), N-(2,4-dimethoxybenzyl)-4-methyl bromoaniline (2a), SN-((1H-indol-3-yl) methylene)-4- methyl bromoaniline (3a) are synthesized and characterized by using the spectroscopic methods of UV, IR and H-1-NMR. Molecular geometry and spectroscopic properties of synthesized compounds are also analyzed by using ab initio calculation methods based on the density functional theory (DFT) in the ground state. The extensive theoretical and experimental FT-IR and UV-vis spectrometry studies of synthesized compounds are performed. The optimized molecular structure and harmonic vibrational frequencies are studied by using B3LYP/6-311++G(d,p) method. Moreover, electronic structures are investigated by using the time dependent density functional theory (TD-DFT) while the energy changes of the parent compounds are examined in a solvent medium by using the polarizable continuum model (PCM). Additionally, the frontier molecular orbital analysis is performed for the Schiff base compounds. The electronic properties of each compound such as; chemical hardness, chemical softness, ionization potential, electron affinity, electronegativity and chemical potential are investigated by utilizing the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energies.

Published
2015

48. Outcomes of mismatched related allogeneic stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Author

van Gorkom, G., van Gelder, M., Ziagkos, D., Koster, L., Koc, Y., van Lint, M., Ciceri, F., Selleslag, D., Blaise, D., Foa, R., Beelen, D., Corradini, P., Moreno, C., Carlson, K., Solano, C., Mueller, L. P., Castagna, L., Tischer, J., Hilgendorf, I., Hallek, M., Bittenbring, J., Theobald, M., Schetelig, J., Kroeger, N., van Gorkom, G., van Gelder, M., Ziagkos, D., Koster, L., Koc, Y., van Lint, M., Ciceri, F., Selleslag, D., Blaise, D., Foa, R., Beelen, D., Corradini, P., Moreno, C., Carlson, K., Solano, C., Mueller, L. P., Castagna, L., Tischer, J., Hilgendorf, I., Hallek, M., Bittenbring, J., Theobald, M., Schetelig, J., and Kroeger, N.

Published
2016

49. Structural vulnerability analysis of electric power distribution grids

Author

Koc, Y. (author), Raman, Abhishek (author), Warnier, Martijn (author), Kumar, Tarun (author), Koc, Y. (author), Raman, Abhishek (author), Warnier, Martijn (author), and Kumar, Tarun (author)

Abstract

Power grid outages cause huge economical and societal costs. Disruptions in the power distribution grid are responsible for a significant fraction of electric power unavailability to customers. The impact of extreme weather conditions, continuously increasing demand, and the over-ageing of assets in the grid, deteriorates the safety of electric power delivery. Measures to analyse the robustness characteristics and to identify vulnerabilities of power grids are of utmost importance. This paper proposes a metric to quantitatively assess the robustness of power distribution grids from a topological point of view. Real-world data is used to demonstrate the applicability of the proposed metric as a tool to assess the criticality of assets in a distribution grid., System Engineering

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results